Bridging the gap between islet allotransplantation and regulatory reform
Drug Discovery World
SEPTEMBER 26, 2024
The root of this issue lies in the outdated regulatory framework that classifies islet cells as drugs rather than organs or tissue. This misclassification imposes stringent drug manufacturing procedures on islet isolation and distribution, hindering timely access to transplantation for those in need.
147 
Let's personalize your content